Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Nausea and vomiting of pregnancy and resource implications: the NVP Impact Study.

Gadsby R, Rawson V, Dziadulewicz E, Rousseau B, Collings H.

Br J Gen Pract. 2018 Dec 17. pii: bjgp18X700745. doi: 10.3399/bjgp18X700745. [Epub ahead of print]

PMID:
30559108
2.

Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease.

Emre M, Bernabei R, Blesa R, Bullock R, Cunha L, Daniëls H, Dziadulewicz E, Förstl H, Frölich L, Gabryelewicz T, Levin O, Lindesay J, Martínez-Lage P, Monsch A, Tsolaki M, van Laar T.

CNS Neurosci Ther. 2010 Aug;16(4):246-53. doi: 10.1111/j.1755-5949.2010.00141.x. Epub 2010 Apr 16. Review.

PMID:
20370805
3.

Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.

Dziadulewicz EK, Bevan SJ, Brain CT, Coote PR, Culshaw AJ, Davis AJ, Edwards LJ, Fisher AJ, Fox AJ, Gentry C, Groarke A, Hart TW, Huber W, James IF, Kesingland A, La Vecchia L, Loong Y, Lyothier I, McNair K, O'Farrell C, Peacock M, Portmann R, Schopfer U, Yaqoob M, Zadrobilek J.

J Med Chem. 2007 Aug 9;50(16):3851-6. Epub 2007 Jul 14.

PMID:
17630726
4.

Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain.

Culshaw AJ, Bevan S, Christiansen M, Copp P, Davis A, Davis C, Dyson A, Dziadulewicz EK, Edwards L, Eggelte H, Fox A, Gentry C, Groarke A, Hallett A, Hart TW, Hughes GA, Knights S, Kotsonis P, Lee W, Lyothier I, McBryde A, McIntyre P, Paloumbis G, Panesar M, Patel S, Seiler MP, Yaqoob M, Zimmermann K.

J Med Chem. 2006 Jan 26;49(2):471-4.

PMID:
16420034
5.

A nonpeptide antagonist reveals a highly glycosylated state of the rabbit kinin B1 receptor.

Fortin JP, Dziadulewicz EK, Gera L, Marceau F.

Mol Pharmacol. 2006 Apr;69(4):1146-57. Epub 2006 Jan 11.

6.

Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core.

Ritchie TJ, Dziadulewicz EK, Culshaw AJ, Müller W, Burgess GM, Bloomfield GC, Drake GS, Dunstan AR, Beattie D, Hughes GA, Ganju P, McIntyre P, Bevan SJ, Davis C, Yaqoob M.

J Med Chem. 2004 Sep 9;47(19):4642-4.

PMID:
15341478
7.

A non-peptide antagonist unusually selective for the human form of the bradykinin B2 receptor.

Marceau F, Fortin JP, Morissette G, Dziadulewicz EK.

Int Immunopharmacol. 2003 Oct;3(10-11):1529-36.

PMID:
12946450
8.

Nonpeptide bradykinin B2 receptor antagonists: conversion of rodent-selective bradyzide analogues into potent, orally-active human bradykinin B2 receptor antagonists.

Dziadulewicz EK, Ritchie TJ, Hallett A, Snell CR, Davies JW, Wrigglesworth R, Dunstan AR, Bloomfield GC, Drake GS, McIntyre P, Brown MC, Burgess GM, Lee W, Davis C, Yaqoob M, Phagoo SB, Phillips E, Perkins MN, Campbell EA, Davis AJ, Rang HP.

J Med Chem. 2002 May 23;45(11):2160-72.

PMID:
12014954
9.

Effects of two novel non-peptide antagonists at the rabbit bradykinin B2 receptor.

Marceau F, Houle S, Bouthillier J, Said NB, Garratt PJ, Dziadulewicz EK.

Peptides. 2001 Sep;22(9):1397-402.

PMID:
11514020
10.

Design of non-peptide CCK2 and NK1 peptidomimetics using 1-(2-nitrophenyl)thiosemicarbazide as a novel common scaffold.

Dziadulewicz EK, Walpole CS, Snell CR, Wrigglesworth R, Hughes GA, Beattie D, Wood JN, Beech MM, Coote PR.

Bioorg Med Chem Lett. 2001 Mar 12;11(5):705-9.

PMID:
11266174
11.

1-(2-Nitrophenyl)thiosemicarbazides: a novel class of potent, orally active non-peptide antagonist for the bradykinin B(2) receptor.

Dziadulewicz EK, Ritchie TJ, Hallett A, Snell CR, Ko SY, Wrigglesworth R, Hughes GA, Dunstan AR, Bloomfield GC, Drake GS, Brown MC, Lee W, Burgess GM, Davis C, Yaqoob M, Perkins MN, Campbell EA, Davis AJ, Rang HP.

J Med Chem. 2000 Mar 9;43(5):769-71. No abstract available.

PMID:
10715143
12.

Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia.

Burgess GM, Perkins MN, Rang HP, Campbell EA, Brown MC, McIntyre P, Urban L, Dziadulewicz EK, Ritchie TJ, Hallett A, Snell CR, Wrigglesworth R, Lee W, Davis C, Phagoo SB, Davis AJ, Phillips E, Drake GS, Hughes GA, Dunstan A, Bloomfield GC.

Br J Pharmacol. 2000 Jan;129(1):77-86.

13.

The design of non-peptide human bradykinin B2 receptor antagonists employing the benzodiazepine peptidomimetic scaffold.

Dziadulewicz EK, Brown MC, Dunstan AR, Lee W, Said NB, Garratt PJ.

Bioorg Med Chem Lett. 1999 Feb 8;9(3):463-8.

PMID:
10091703

Supplemental Content

Loading ...
Support Center